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Different viruses are currently being assessed for their capacity to function as anti-tumor agents, supplementing conventional cancer therapies. Here we report on the potentials of a novel oncolytic virus, the murine hepatitis coronavirus (MHV), in destroying tumor cells *in vitro*. MHV is a positive strand RNA virus displaying strong species specificity. It has a replication cycle of only 10-15 hours, and efficiently kills cells by fusion of the infected cells with their neighboring cells. Previous studies showed (Kuo L. *et al*., J Virol. 2000;74:1393-406) that the murine host cell tropism of MHV could be changed by substituting its spike protein, necessary for cellular binding and internalization, by the feline coronavirus counterpart. The resulting recombinant coronavirus fMHV only infects feline cells via the feline aminopeptidase N (fAPN) receptor. In this study we showed that the human tumor cell lines HeLa, OVCAR-3, Widr, Caco-2, HCT-81, and HepG2 cells were rendered susceptible to fMHV, as well as to its derivative fMHVdel2aHE, which lacks the non-essential genes 2a and HE, by transfection with a fAPN expression construct. Furthermore, fMHV and fMHVdel2aHE infections of HeLa and OVCAR-3 cells stably expressing fAPN, resulted in rapid killing of both cell cultures starting at 12-24 h post-inoculation. In addition, 3-D multilayer OVCAR-fAPN spheroids established from 5 x 10^4^ cells could be eradicated within 7 days of inoculation with 5 x 10^4^ PFU fMHV, which was not accomplished by inoculating 5 x 10^8^ IU wild-type adenovirus, a DNA virus used frequently in studies on tumor eradication. The deletion mutant fMHVdel2aHE was attenuated as compared to fMHV, although it was still as efficient in destroying OVCAR-fAPN spheroids as wild-type adenovirus using these dosages. These results show that infections with coronaviruses, if retargeted to human tumor cells, cause rapid and efficient death of these cells. Hence, tumor-targeted coronaviruses seem interesting as anti-tumor agents.
